Search results for "Nootropic Agents"

showing 10 items of 20 documents

Piracetam counteracts the effects of amitriptyline on inhibitory avoidance in CD1 mice.

2005

The purpose of the present work was to study the effects of amitriptyline on animal cognition in relation to some characteristics of its therapeutic effects. The modulation of acute and chronic effects of amitriptyline on inhibitory avoidance in male and female mice by piracetam was investigated. In Experiment 1, mice were subjected to the training phase of inhibitory avoidance conditioning 60 min after acute piracetam (100 mg/kg) or physiological saline administration. Immediately after the behavioural task, they received a single injection of the tricyclic antidepressant amitriptyline (30 mg/kg) or physiological saline. Twenty-four hours later, subjects were tested for avoidance. In Exper…

MaleElevated plus mazemedicine.medical_specialtymedicine.drug_classAmitriptylineTricyclic antidepressantPharmacologyAntidepressive Agents TricyclicInhibitory postsynaptic potentialDrug Administration ScheduleStatistics NonparametricBehavioral NeuroscienceMiceSex FactorsMemorymedicineAvoidance LearningAnimalsAmitriptylineDrug InteractionsPsychiatryNootropic AgentsAnalysis of VarianceReactive inhibitionTherapeutic effectPiracetamReactive InhibitionPiracetamFemaleAnalysis of variancePsychologymedicine.drugBehavioural brain research
researchProduct

Pregnenolone sulphate enhances spatial orientation and object discrimination in adult male rats: Evidence from a behavioural and electrophysiological…

2013

Abstract Neurosteroids can alter neuronal excitability interacting with specific neurotransmitter receptors, thus affecting several functions such as cognition and emotionality. In this study we investigated, in adult male rats, the effects of the acute administration of pregnenolone-sulfate (PREGS) (10 mg/kg, s.c.) on cognitive processes using the Can test, a non aversive spatial/visual task which allows the assessment of both spatial orientation–acquisition and object discrimination in a simple and in a complex version of the visual task. Electrophysiological recordings were also performed in vivo , after acute PREGS systemic administration in order to investigate on the neuronal activati…

MaleNeuroactive steroidAction PotentialsHippocampusHippocampusSettore BIO/09 - FisiologiaBehavioral NeurosciencePregnenolone-sulphate Spatial orientation Object discrimination Perirhinal cortex HippocampusDiscrimination PsychologicalNeurotransmitter receptorOrientationPerirhinal cortexmedicineAnimalsPremovement neuronal activityRats WistarNootropic AgentsCerebral CortexNeuronsLong-term potentiationCognitionRatsElectrophysiologymedicine.anatomical_structurePregnenoloneSpace PerceptionSettore BIO/14 - FarmacologiaPsychologyNeuroscience
researchProduct

What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement

2012

Pharmacological cognitive enhancement (CE) is a topic of increasing public awareness. In the scientific literature on student use of CE as a study aid for academic performance enhancement, there are high prevalence rates regarding the use of caffeinated substances (coffee, caffeinated drinks, caffeine tablets) but remarkably lower prevalence rates regarding the use of illicit/prescription stimulants such as amphetamines or methylphenidate. While the literature considers the reasons and mechanisms for these different prevalence rates from a theoretical standpoint, it lacks empirical data to account for healthy students who use both, caffeine and illicit/prescription stimulants, exclusively f…

MaleNon-Clinical MedicinePsychopharmacologymedicine.medical_treatment610 Medizinlcsh:MedicineScientific literatureMedical LawSocial and Behavioral SciencesDrug UsersCognition610 Medical sciencesMedical SociologyHuman PerformancePsychologylcsh:ScienceNootropic AgentsProblem Solvingmedia_commonPsychiatryMultidisciplinarySubstance AbuseQualitative StudiesSubstance abuseMental HealthNeurologyHealth Education and AwarenessMedicineFemalePublic HealthBehavioral and Social Aspects of HealthResearch ArticleAdultMedical Ethicsmedicine.medical_specialtyDrugs and DevicesPrescription DrugsUniversitiesSubstance-Related DisordersClinical Research DesignScience Policymedia_common.quotation_subjectCognitive NeuroscienceDecision MakingNeuropharmacologyNeuropsychologyCaffeinemedicineHumansMedical prescriptionStudentsPsychiatryBiologyBehaviorHealth Care Policybusiness.industryIllicit DrugsAddictionlcsh:RCognitive PsychologyBioethicsmedicine.diseaseStimulantScience Educationlcsh:QCentral Nervous System StimulantsCitationAttributionbusinessLawMedical ethicsNeuroscience
researchProduct

The role of pregnenolone sulphate in spatial orientation-acquisition and retention: An interplay between cognitive potentiation and mood regulation

2013

Abstract Neurosteroids can alter neuronal excitability interacting with specific neurotransmitter receptors, thus affecting several functions such as cognition and emotionality. In this study, we investigated, in adult male rats, the effects of the acute administration of pregnenolone-sulfate (PREGS) (10 mg/Kg, s. c.) on cognitive processes using the Can test, a non aversive spatial/visual task which allows the assessment of spatial information-acquisition during the baseline training, and of memory retention in the longitudinal study. Furthermore, on the basis of PREGS pharmacological profile, the modulation of depressive-like behaviour was also evaluated in the forced swim test (FST). Our…

MalePregnenolone-sulphate Spatial orientation-acquisition Spatial orientation-retention Cognitive map Depressive-like behaviouNeuroactive steroidMotor ActivityDevelopmental psychologyBehavioral NeuroscienceCognitionMemoryEmotionalityOrientationmedicineAnimalsLearningLongitudinal StudiesRats WistarNootropic AgentsSwimmingDepressionWorking memoryCognitionLong-term potentiationGeneral Medicinemedicine.diseaseRatsAffectMoodMood disordersData Interpretation StatisticalPregnenoloneSpace PerceptionSettore BIO/14 - FarmacologiaAnimal Science and ZoologyPsychologyNeuroscienceBehavioural despair test
researchProduct

Controlled Iontophoretic Delivery in Vitro and in Vivo of ARN14140—A Multitarget Compound for Alzheimer’s Disease

2019

ARN14140 is a galantamine-memantine conjugate that acts upon both cholinergic and glutamatergic pathways for better management of Alzheimer's disease. Poor oral bioavailability and pharmacokinetics meant that earlier preclinical in vivo studies employed intracerebroventricular injection to administer ARN14140 directly to the brain. The aim of the present study was to evaluate the feasibility of using constant current transdermal iontophoresis for the noninvasive systemic delivery of ARN14140 and to quantify the amounts present in the blood and the brain. Preliminary experiments in vitro were performed using porcine skin and validated with human skin. Cumulative ARN14140 permeation across th…

MaleSwineSkin Absorptionbrain deliveryBiological AvailabilityPharmaceutical ScienceHuman skin02 engineering and technologyPharmacologyAdministration Cutaneous030226 pharmacology & pharmacyPermeability03 medical and health sciences0302 clinical medicineDrug StabilityPharmacokineticsIn vivoDrug DiscoveryARN14140AnimalsBrain/metabolismHumansSkin/metabolismMedicineTissue DistributionRats WistarNootropic Agents/administration & dosage/pharmacokineticsTransdermalddc:615galantamine-memantine conjugateAlzheimer Disease/drug therapyIontophoresisbusiness.industryGalantamine/administration & dosage/pharmacokineticsiontophoresiIontophoresisMemantine/administration & dosage/pharmacokinetics021001 nanoscience & nanotechnologyIn vitroRatsBioavailabilityHeterocyclic Compounds 4 or More Rings/administration & dosage/pharmacologytransdermalFeasibility StudiesMolecular MedicineCholinergic0210 nano-technologybusinessMolecular Pharmaceutics
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Dementia, neuropsychiatric symptoms, and the use of psychotropic drugs among older people who receive domiciliary care: a cross-sectional study.

2013

ABSTRACTBackground:The objective of this study was to (a) determine the prevalence of cognitive impairment, dementia, and neuropsychiatric symptoms (NPSs) among home-dwelling people, 70 years and older (70+ years), who receive domiciliary care, and (b) describe their use of psychotropic drugs. Few studies have investigated dementia among people receiving in-home care.Methods:A sample (N = 1,000) representative of people aged 70+ years receiving domiciliary care was randomly recruited for participation. A standardized interview with the participants and their next of kin were performed using well-established assessment scales. Two clinical experts independently diagnosed dementia according t…

Malemedicine.medical_specialtyNext of kinCross-sectional studyApathyNeuropsychological TestsIrritabilitymedicineDementiaHumansApathyPsychiatryDepression (differential diagnoses)Nootropic AgentsAgedAged 80 and overPsychotropic Drugsbusiness.industryNorwaymedicine.diseaseAnxiety DisordersHome Care ServicesAntidepressive AgentsDrug UtilizationIrritable MoodPsychiatry and Mental healthClinical PsychologyCross-Sectional StudiesStructured interviewAnxietyDementiaFemaleGeriatrics and Gerontologymedicine.symptombusinessGerontologyInternational psychogeriatrics
researchProduct

Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat.

2009

Summary Purpose:  We evaluated the possible additive effect induced by the administration of the anticonvulsant vigabatrin (VGB) and cholecystokinin-8 sulfate (CCK-8S) on an experimental model of partial complex seizures (maximal dentate gyrus activation, MDA). Moreover, the functional involvement of γ-aminobutyric acid (GABA) neurotransmission was tested by iontophoretically administering bicuculline (GABA receptor antagonist) in the dentate gyrus. Methods:  Urethane anesthetized rats were pretreated with VGB (50, 100 or 200 mg/kg, i.p.) or CCK-8S (8 nmol/kg, i.p.) alone or coadministered with VGB (50 mg/kg, i.p.). Dentate gyrus epileptic activity was obtained through the repetitive electr…

Malemedicine.medical_treatmentStimulationConvulsantsNeurotransmissionPharmacologyBicucullineRat Partial epilepsy Vigabatrin Cholecystokinin-8 sulfate ControlVigabatrinDrug Administration ScheduleSincalideVigabatrinEpilepsy Complex PartialmedicineReaction TimeAnimalsRats WistarEvoked PotentialsNootropic AgentsAnalysis of VarianceIontophoresisDose-Response Relationship DrugChemistryDentate gyrusDrug SynergismBicucullineGABA receptor antagonistElectric StimulationRatsDisease Models AnimalAnticonvulsantNeurologyAnesthesiaDentate GyrusAnticonvulsantsDrug Therapy CombinationNeurology (clinical)medicine.drugEpilepsia
researchProduct

Glucose plus choline improve passive avoidance behaviour and increase hippocampal acetylcholine release in mice.

2001

The present study tests the effects of glucose and choline, the biosynthetic precursors of acetylcholine, on passive avoidance behaviour and hippocampal acetylcholine release measured by microdialysis in awake mice. Glucose (10 and 30mg/kg) or choline chloride (6-60mg/kg), given by i.p. injection immediately after training, dose-dependently enhanced retention in an inhibitory avoidance task. Combinations of low doses of glucose (10mg/kg) and choline chloride (20mg/kg) which alone were submaximally effective significantly increased retention latencies in a synergistic manner, an effect which was sensitive to atropine (0.5mg/kg). This beneficial effect vanished when higher doses of glucose or…

medicine.medical_specialtyMicrodialysisMicrodialysisHippocampal formationHippocampusSynaptic TransmissionCholinechemistry.chemical_compoundMiceMemoryInternal medicinemedicineAvoidance LearningCholineAnimalsNeurotransmitterNootropic AgentsMice Inbred BALB CGeneral NeuroscienceAcetylcholineAtropineEndocrinologyGlucosechemistryExploratory BehaviorCholinergicFemaleAcetylcholinemedicine.drugCholine chlorideNeuroscience
researchProduct

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

2001

Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease. Interestingly, the clinical potency of these drugs does not correlate well with their activity as cholinesterase inhibitors, nor is their action as short lived as would be expected from purely symptomatic treatment. A few cholinesterase inhibitors, including galantamine, produce beneficial effects even after drug treatment has been terminated. These effects assume modes of action other than mere esterase inhibition and are capable of inducing systemic changes. We have recently discovered a mechanism that could account, at least in part, for the above-mentioned unex…

medicine.medical_specialtyPatch-Clamp TechniquesReceptors NicotinicPharmacologyCell LineMiceAllosteric RegulationAlzheimer DiseaseInternal medicinemedicineGalantamineAnimalsHumansNootropic AgentsBiological PsychiatryCholinesteraseAcetylcholine receptorNeuronsbiologyGalantamineChemistryNicotinic acetylcholine receptorNicotinic agonistEndocrinologyMechanism of actionTacrinebiology.proteinCholinesterase Inhibitorsmedicine.symptomAllosteric SiteAcetylcholinemedicine.drugBiological Psychiatry
researchProduct